Celyad Oncology SA

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:35:16 2024-04-26 am EDT			5-day change	1st Jan Change
0.335 ^EUR	+6.35%		-1.33%	-14.10%

Apr. 04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 09	Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	MT

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021

March 24, 2022 at 05:06 pm EDT

Celyad Oncology SA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was EUR 26.51 million compared to EUR 17.2 million a year ago. Basic loss per share from continuing operations was EUR 1.7 compared to EUR 1.23 a year ago.

Latest news about Celyad Oncology SA

Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Celyad Oncology Seeks Termination of Reporting Obligations to US SEC	Feb. 09	MT
Celyad Oncology CEO Resigns	Dec. 05	MT
Celyad Oncology CEO Steps Down for Personal Reasons	Dec. 04	MT
Celyad Oncology SA Announces Executive Change	Dec. 04	CI
Celyad Oncology Sa Announces Executive Change	Dec. 04	CI
Celyad Oncology SA announced that it has received ?9.794 million in funding from CFIP CLYD (UK) Limited, Fortress Investment Group LLC, Tolefi S.A.	Nov. 13	CI
Celyad Oncology to Cancel American Depository Receipt Program in October	23-09-26	MT
Transcript : Celyad Oncology SA, H1 2023 Earnings Call, Sep 05, 2023	23-09-05
Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-04	CI
Celyad Oncology Secures EUR10 Million via Private Placement With Historical Investors	23-08-25	MT
Celyad Oncology SA announced that it expects to receive ?9.794 million in funding from Fortress Investment Group LLC, Tolefi S.A., and other investors	23-08-23	CI
Celyad Oncology SA(OTCUS:CYAD.Y) dropped from NASDAQ Composite Index	23-05-18	CI
Celyad Oncology's American Depositary Shares to Be Delisted from Nasdaq	23-05-16	MT
Celyad Oncology Receives Delisting Notice From Nasdaq	23-05-15	MT
Forecast-Beating Apple Results Lift Exchange-Traded Funds, Equity Futures Pre-Bell Friday	23-05-05	MT
Belgium's Celyad Oncology to Delist ASDs from Nasdaq	23-05-05	MT
Celyad Oncology to Delist From Nasdaq Global Market	23-05-05	MT
Celyad Oncology in Breach of Nasdaq's Listing Rule	23-04-04	MT
Transcript : Celyad Oncology SA, 2022 Earnings Call, Mar 24, 2023	23-03-24
Celyad Oncology SA Appoints Georges Rawadi as its New Chief Executive Officer	23-03-24	CI
Celyad Oncology Names Georges Rawadi as Chief Executive	23-03-24	MT
Celyad Oncology Appoints New CEO	23-03-24	MT
Celyad Oncology SA Auditor Raises 'Going Concern' Doubt	23-03-22	CI
Sector Update: Health Care Stocks' Late Recovery Stalls	23-03-15	MT

Chart Celyad Oncology SA

Duration

Period

More charts

Company Profile

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELYAD ONCOLOGY SA	-14.10%	13.98M
IQVIA HOLDINGS INC.	+2.03%	42.59B
MODERNA, INC.	+7.33%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+9.22%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.03%	18.17B
MEDPACE HOLDINGS, INC.	+27.38%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.09%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.05%	11.1B

Other Biotechnology & Medical Research